

BARD1 APPOINTS DR PETER FRENCH AS CSO TO LEAD ITS EXPANDED R&D PORTFOLIO

- **BARD1 appoints new CSO following Sienna acquisition**
- **Dr Peter French to lead development of broader R&D programs towards value-generating technical and commercial outcomes**
- **Dr Irmgard Irminger-Finger to become Founding Scientist focused on advancing the BARD1 biomarker technology**

Perth, Australia, 24 July 2020: BARD1 Life Sciences Limited (ASX:BD1) (**BARD1** or the **Company**), a medical diagnostics company, today announced the strengthening of its leadership team with the appointment of Dr Peter French PhD as Chief Scientific Officer (CSO), effective 17 August 2020.

Dr French will lead the Company's broader Research and Development (R&D) programs following the acquisition of Sienna Cancer Diagnostics Ltd (Sienna). The acquisition provides the Company with a broad technology portfolio comprising the BARD1 biomarker technology, the hTERT assay, SIEN-NET™ biomarker capture technology and the SubB2M pan-cancer probe. Dr French will be responsible for creating new intellectual property from the Company's multiple technology platforms, initiating new research projects and collaborations, and advancing its product development programs towards commercial outcomes.

Dr French BSc MSc PhD MBA is a leading biotechnology executive and respected scientist with extensive CSO, CEO and director experience. He has a strong track record in commercialising medical innovations with over 40 years' scientific expertise in cell and molecular biology and over 40 peer reviewed publications across oncology, immunology, microbiology and neuroscience. Most recently, Dr French provided strategic and scientific consulting services to a number of biotechnology companies including Sienna and BARD1. His previous industry roles included being executive director of AusDiagnostics Pty Ltd, Bioxyne Ltd and BCAL Diagnostics, Managing Director of gene therapy company Benitec Biopharma Ltd, and founder and non-executive director of Cryosite Ltd (ASX:CTE).

Dr French also had a successful academic career as Principal Scientist at the Centre for Immunology, St Vincent's Hospital and Post-Doctoral Research Scientist at the Children's Medical Research Foundation. He was awarded the Faculty of Science Alumni Achievement Award for Innovation and Entrepreneurship in 2019 from the University of Sydney, and was named as one of five Innovators of Influence in 2015 by the Australian Academy of Technology and Engineering. Dr French is currently Non-Executive Chairman of Mediland Pharm Ltd (ASX:MPH) and Penao Pty Ltd.

Dr French said: "I am excited to join the expanded BARD1 team and work with Dr Irminger-Finger to continue her translational work on the BARD1 autoantibody tests, as well as to combine the group's innovative technology platforms to generate next-generation products and help take the Company to the next level. I am strongly motivated to translate medical innovations into commercially viable products that help patients. My key focus will be to advance our research programs and drive the development of our diagnostics pipeline to successful commercial and clinical outcomes."

BARD1 CEO Dr Learne Hinch said: "We are extremely pleased to welcome Dr Peter French to the BARD1 team. He is ideally suited to the expanded CSO role with his strong commercial and academic background, diagnostics development experience and track record commercialising medical innovations. This is a key appointment as we seek to build a leading diagnostics company that leverages our innovative technologies across our in-house, partnered diagnostic programs and future acquisitions. Whilst his focus will be on the development of the Company's technologies for use as novel screening and diagnostic tests for a range of cancers, including breast, ovarian, lung and prostate cancers, he will also support product extensions to the marketed hTERT test for bladder cancer."

Dr Irmgard Irminger-Finger BSc MSc PhD, the current BARD1 CSO and Executive Director will take on the role of Founding Scientist (BARD1), focused on working with Dr French to expand applications for the

BARD1 biomarker technology and advance the BARD1 autoantibody program. Dr Irminger-Finger said: “I am very satisfied with our progress in translating the BARD1 science from biomarker discovery towards potential autoantibody blood tests for early detection of cancer, which is a major achievement. We are now entering the next phase of development and I am very confident in handing over to Dr French to advance the BARD1 autoantibody tests into commercially viable products, as well as to expand the BARD1 portfolio across multiple applications. I look forward to working with Dr French in the advancement of our broader R&D programs to value-generating milestones.”

Authorised for release by Company Secretary, Pauline Collinson.

COMPANY CONTACTS:

Dr Leearne Hinch

CEO

E leearne@bard1.com

M +61 400 414 416

Peter Gunzburg

Chairman

E peter@bard1.com

ABOUT BARD1 LIFE SCIENCES LTD

BARD1 Life Sciences Ltd (ASX:BD1) (**BARD1** or the **Company**) is an Australian medical technology company focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer. BARD1 owns proprietary technologies with potential diagnostic and therapeutic applications across multiple cancers. The pipeline includes diagnostic tests in development for early detection of ovarian, breast, lung and other cancers. BARD1’s vision is to detect cancer earlier and save lives. For more information on BARD1, see www.bard1.com.

FORWARD LOOKING STATEMENTS

This announcement contains certain ‘forward-looking statements’ within the meaning of the securities laws of applicable jurisdictions. Forward-looking statements can generally be identified by the use of forward-looking words such as ‘may,’ ‘should,’ ‘expect,’ ‘anticipate,’ ‘estimate,’ ‘scheduled’ or ‘continue’ or the negative version of them or comparable terminology. Any forecasts or other forward-looking statements contained in this announcement are subject to known and unknown risks and uncertainties and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. The Company does not give any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur and you are cautioned not to place undue reliance on forward-looking statements.